Vera Therapeutics (VERA) Times Interest Earned (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Times Interest Earned came in at -$0.74 in Q1 2026, up 84.96% YoY from -$0.4 in Q1 2025, and up 56.01% on a QoQ basis from -$1.68 in Q4 2025.
Vera Therapeutics (VERA) Times Interest Earned (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Times Interest Earned data on file, last reported at -$0.74 in Q1 2026.
- Quarterly Times Interest Earned rose 84.96% year-over-year to -$0.74 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.26 (up 60.44% YoY) and the FY2025 annual result came in at -$1.21, down 24.96% from the prior year.
- Times Interest Earned grew to -$0.74 in Q1 2026, from -$1.68 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.74 in Q1 2026 to a low of -$60.07 in Q4 2022.
- A 5-year average of -$13.37 and a median of -$4.73 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned tumbled 1252.35% — and 2023, when it jumped 96.67%.
- Tracing VERA's Times Interest Earned over 5 years: stood at -$60.07 in 2022, then jumped by 96.67% to -$2.0 in 2023, then tumbled by 1205.13% to -$26.14 in 2024, then jumped by 93.58% to -$1.68 in 2025, then jumped by 56.01% to -$0.74 in 2026.
- The last three Times Interest Earned figures came in at -$0.74 (Q1 2026), -$1.68 (Q4 2025), and -$26.03 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | -0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.60 |
| Mar 31, 2026 | -0.74 |
| Dec 31, 2025 | -1.68 |
| Sep 30, 2025 | -26.03 |
| Jun 30, 2025 | -4.29 |
| Mar 31, 2025 | -4.91 |
| Dec 31, 2024 | -26.14 |
| Sep 30, 2024 | -6.26 |
| Jun 30, 2024 | -3.03 |
| Mar 31, 2024 | -4.73 |
| Dec 31, 2023 | -2.00 |
| Sep 30, 2023 | -3.84 |
| Jun 30, 2023 | -17.19 |
| Mar 31, 2023 | -35.76 |
| Dec 31, 2022 | -60.07 |
| Sep 30, 2022 | -2.92 |
| Jun 30, 2022 | -1.74 |
| Mar 31, 2022 | -25.95 |
| Mar 31, 2021 | -1.92 |
| Dec 31, 2020 | 357.65 |